JACC:糖尿病伴多支冠脉病变患者的手术选择

2019-10-22 不详 MedSci原创

对于糖尿病伴多支冠脉病变(CAD)患者,FREEDOM临床试验结果显示冠脉搭桥(CABG)要总体优于冠脉介入(PCI)治疗,但PCI在临床中治疗多支冠脉病变还是比较广泛。本研究的目的旨在将FREEDOM临床试验结果进行个体化分析。本研究纳入分析了FREEDOM临床试验中1900名患者,使用基于基线协变量和治疗相互作用的模型对患者术后5年主要不良心血管事件(MACE)和1年心绞痛进行评估。最终,共有

对于糖尿病伴多支冠脉病变(CAD)患者,FREEDOM临床试验结果显示冠脉搭桥(CABG)要总体优于冠脉介入(PCI)治疗,但PCI在临床中治疗多支冠脉病变还是比较广泛。本研究的目的旨在将FREEDOM临床试验结果进行个体化分析。

本研究纳入分析了FREEDOM临床试验中1900名患者,使用基于基线协变量和治疗相互作用的模型对患者术后5年主要不良心血管事件(MACE)和1年心绞痛进行评估。最终,共有346名患者出现5年后MACE,310名患者出现1年后心绞痛,通过两种模型发现,PCI未优于CABG,但有54.5%的患者CABG在5年MACE方面优于PCI,而对于抽烟患者,CABG100%优于PCI。

本研究建立新的风险预测模型,可帮助糖尿病伴多支冠脉病变患者选择合适的手术方式。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2076443, encodeId=593520e64435c, content=<a href='/topic/show?id=1e973098e62' target=_blank style='color:#2F92EE;'>#冠脉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30987, encryptionId=1e973098e62, topicName=冠脉病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat Nov 30 09:05:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035551, encodeId=9d96203555173, content=<a href='/topic/show?id=6da530988d0' target=_blank style='color:#2F92EE;'>#冠脉病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30988, encryptionId=6da530988d0, topicName=冠脉病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Sat May 02 18:05:00 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854547, encodeId=1646185454e50, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Jun 19 18:05:00 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326373, encodeId=cf7213263e371, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Oct 24 13:05:00 CST 2019, time=2019-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042786, encodeId=3b881042e8645, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Oct 23 01:05:00 CST 2019, time=2019-10-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2076443, encodeId=593520e64435c, content=<a href='/topic/show?id=1e973098e62' target=_blank style='color:#2F92EE;'>#冠脉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30987, encryptionId=1e973098e62, topicName=冠脉病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat Nov 30 09:05:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035551, encodeId=9d96203555173, content=<a href='/topic/show?id=6da530988d0' target=_blank style='color:#2F92EE;'>#冠脉病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30988, encryptionId=6da530988d0, topicName=冠脉病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Sat May 02 18:05:00 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854547, encodeId=1646185454e50, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Jun 19 18:05:00 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326373, encodeId=cf7213263e371, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Oct 24 13:05:00 CST 2019, time=2019-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042786, encodeId=3b881042e8645, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Oct 23 01:05:00 CST 2019, time=2019-10-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2076443, encodeId=593520e64435c, content=<a href='/topic/show?id=1e973098e62' target=_blank style='color:#2F92EE;'>#冠脉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30987, encryptionId=1e973098e62, topicName=冠脉病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat Nov 30 09:05:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035551, encodeId=9d96203555173, content=<a href='/topic/show?id=6da530988d0' target=_blank style='color:#2F92EE;'>#冠脉病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30988, encryptionId=6da530988d0, topicName=冠脉病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Sat May 02 18:05:00 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854547, encodeId=1646185454e50, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Jun 19 18:05:00 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326373, encodeId=cf7213263e371, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Oct 24 13:05:00 CST 2019, time=2019-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042786, encodeId=3b881042e8645, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Oct 23 01:05:00 CST 2019, time=2019-10-23, status=1, ipAttribution=)]
    2020-06-19 hbwxf
  4. [GetPortalCommentsPageByObjectIdResponse(id=2076443, encodeId=593520e64435c, content=<a href='/topic/show?id=1e973098e62' target=_blank style='color:#2F92EE;'>#冠脉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30987, encryptionId=1e973098e62, topicName=冠脉病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat Nov 30 09:05:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035551, encodeId=9d96203555173, content=<a href='/topic/show?id=6da530988d0' target=_blank style='color:#2F92EE;'>#冠脉病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30988, encryptionId=6da530988d0, topicName=冠脉病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Sat May 02 18:05:00 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854547, encodeId=1646185454e50, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Jun 19 18:05:00 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326373, encodeId=cf7213263e371, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Oct 24 13:05:00 CST 2019, time=2019-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042786, encodeId=3b881042e8645, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Oct 23 01:05:00 CST 2019, time=2019-10-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2076443, encodeId=593520e64435c, content=<a href='/topic/show?id=1e973098e62' target=_blank style='color:#2F92EE;'>#冠脉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30987, encryptionId=1e973098e62, topicName=冠脉病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sat Nov 30 09:05:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035551, encodeId=9d96203555173, content=<a href='/topic/show?id=6da530988d0' target=_blank style='color:#2F92EE;'>#冠脉病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30988, encryptionId=6da530988d0, topicName=冠脉病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Sat May 02 18:05:00 CST 2020, time=2020-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854547, encodeId=1646185454e50, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Jun 19 18:05:00 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326373, encodeId=cf7213263e371, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Oct 24 13:05:00 CST 2019, time=2019-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042786, encodeId=3b881042e8645, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Oct 23 01:05:00 CST 2019, time=2019-10-23, status=1, ipAttribution=)]
    2019-10-23 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

Sci Rep:根治性膀胱切除术后不良心血管事件风险因素分析

根治性膀胱切除术时肌肉浸润性膀胱肿瘤和非浸润性膀胱肿瘤的标准治疗方法,但是也伴随着高发生率的术后并发症,包括了严重的不良心血管事件(MACE)。舒张期功能障碍与术后并发症相关。最近,有研究人员评估了围手术期风险因素,包括了与术后6个月内与MACE有关的舒张期功能障碍。研究共包括了546名经历了选择根治性膀胱切除术的患者,研究发现,根治性膀胱切除术后6个月内,43(7.9%)名患者发展为MACE。M

JACC:联合冠脉CTA可改善冠心病预后

在SCOT-HEART临床试验中,冠脉CTA的运用可以减少稳定型胸痛患者的心源性死亡率。本研究的目的旨在评估该临床试验的五年临床结局及可能机制。本研究将4146名患者随机分成标准治疗组和标准治疗联合冠脉CTA组。在未被诊断为冠心病心绞痛的患者中,冠脉CTA可以降低主要终点事件发生率(p < 0.001)。在接受冠脉CTA检测患者中,第一年的冠脉血运重建率更高( [HR]: 1.21; 95%

如何让你的论文吸引主编?|GW-ICC2019

导语:大会内容抢先看~

JAMA Psychiatry:神经性贪食症与女性长期心血管事件风险

研究证实,神经性贪食症与任何心血管疾病的长期风险有关,包括缺血性心脏事件和传导障碍以及死亡。